NCT06162377View on ClinicalTrials.gov

"Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A Window of Opportunity Pilot Study."

PHASE4RecruitingINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

January 10, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG

Methylnaltrexone

Given by SC (injection)

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER